BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 2751676)

  • 1. Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and biscoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells.
    Yamamoto S; Hui PZ; Fukuda Y; Tatsumi K; Mino M
    Biochem Int; 1989 Jun; 18(6):1077-83. PubMed ID: 2751676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
    Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine.
    Kato T; Suzumura Y
    J Natl Cancer Inst; 1987 Sep; 79(3):527-32. PubMed ID: 3476792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.
    Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
    Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
    Tsuruo T
    Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
    Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
    Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
    Adwankar MK; Chitnis MP
    Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor activities and mechanisms of action of harringtonine and homoharringtonine].
    Kato T; Takamoto S; Mizutani M; Hato M; Ota K
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2393-9. PubMed ID: 6497398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
    Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
    Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids.
    Hasegawa H; Sung JH; Matsumiya S; Uchiyama M; Inouye Y; Kasai R; Yamasaki K
    Planta Med; 1995 Oct; 61(5):409-13. PubMed ID: 7480200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 May; 43(5):2267-72. PubMed ID: 6831450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line.
    Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K
    Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
    Naito M; Tsuruo T
    Cancer Res; 1989 Mar; 49(6):1452-5. PubMed ID: 2924298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cepharanthine on doxorubicin cytotoxicity in P388 murine leukemia cells in vitro and in vivo.
    Fujimura T; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1991 Feb; 71(2):235-8. PubMed ID: 2047569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
    Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Rouse W; Riegler F
    Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.